Recent Updates
Recently added Catalysts

Azithromycin microspheres 2.0 single dose

Phase 3

Community-Acquired Pneumonia | Small molecule | Infectious Disease |Pfizer, Inc.|Last Updated: May 10, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment47

FDA Designations

No designations recorded

Clinical trial landscape

Azithromycin microspheres 2.0 single dose · 1 trial · 1 indication

Phase 3 1
NCT00140023Azithromycin Microspheres in Patients With Low Risk Community Acquired PneumoniaCommunity-Acquired Pneumonia
COMPLETED47 Analytics
PHASE3COMPLETED
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
Community-Acquired Pneumonia
NCT0014002347
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the clinical efficacy of 2.0 g single dose of azithromycin microspheres in Low Risk CAP.

Secondary Endpoints

To assess bacteriological efficacy of 2.0 g single dose of azithromycin microspheres. To assess the safety and tolerability of 2.0 g single dose of azithromycin microspheres.
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
Azithromycin microspheres 2.0 single doseDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Male or female, 18 years age or older, for whom oral, outpatient therapy is indicated. * Diagnosis of CAP as manifested by at least 3 or more of the following: * cough, pleuritic chest pain, fever (temperature of \>37.8 C to \<40 C), auscultatory findings on pulmonary examinat...

Countries:Philippines
Unlock Eligibility Criteria